The FDA released draft guidance on June 2 that could accelerate genome editing therapies by allowing companies to leverage existing scientific knowledge. The policy, designed to avoid repeating studies, is especially critical for rare diseases with small patient populations and high costs.
Under the proposal, companies can use prior manufacturing, nonclinical, and clinical data, including analytical testing, stability data, and platform knowledge, if they demonstrate relevance to the new therapy.
FDA officials stress the goal is efficiency without compromising safety. Karim Mikhail, Acting Director of the Center for Biologics Evaluation and Research, said the agency wants to get safe and effective cell and gene therapies to patients faster. Vijay Kumar, Acting Director of the Office of Therapeutic Products, emphasized: “Leveraging prior knowledge does not mean lowering the bar.”
The public has 90 days to comment on the draft.
North America currently leads the global genome editing market, accounting for 44% of it in 2025.